Laureate, Boehringer Enter Manufacturing Partnership

Laureate Pharma, Inc. has entered a preferred partnership agreement with Boehringer Ingelheim, allowing Laureate’s clients to gain access to BI’s manufacturing technology platform for biopharmaceutical products produced by mammalian cell culture.

Through this collaboration, Laureate will now offer its clients bioprocessing services that include: creation and development of production cell lines using Boehringer’s BI HEX expression system; full-service process development and manufacture of early stage clinical supplies at Laureate’s cGMP manufacturing facility in Princeton, NJ; and access to Boehringer’s large-scale commercial production at its facility in Biberach, Germany. The two companies will harmonize bioprocessing methods to ensure seamless transfer of manufacturing activities from Laureate to Boehringer, according to a Laureate statement.

“We are delighted to announce our preferred partnership with Boehringer Ingelheim and view it as a great way to provide our clients with a complete path from clinical-scale production at Laureate to large-scale commercial manufacturing at Boehringer Ingelheim,” said Robert J. Broeze, Ph.D., president and chief executive officer of Laureate Pharma. “Working together, Laureate Pharma and Boehringer Ingelheim offer a comprehensive menu of manufacturing solutions in the U.S. and Europe.”

“With Laureate Pharma, Boehringer Ingelheim complements its worldwide strategic manufacturing network with a strong partner for process development and clinical material supply. Our process know-how allows state-of-the-art and time to clinic development at Laureate as well as smooth technology transfer to Boehringer Ingelheim’s commercial manufacturing,” commented Dr. Rolf G. Werner, senior vice president, corporate division biopharmaceuticals, Boehringer Ingelheim.